Acentra Health prepares 2026 SUPPORT Act DUR report
Trusted by teams at
Description
Texas Medicaid’s drug utilization review program is supported by Acentra Health, which prepared the 2026 SUPPORT Act criteria report outlining opioid safety, pediatric antipsychotic monitoring, and fraud and abuse interventions. The biannual report provides detailed intervention criteria and population targets to demonstrate compliance with federal Medicaid pharmacy requirements under the SUPPORT Act.
Contract Details
Vendor
ACENTRA HEALTH
Agency
Texas Health and Human Services, TX
Contract Type
PROFESSIONAL_SERVICES
Document Date
April 19, 2026
Contract Term
Biannual SUPPORT Act DUR criteria review and reporting for 2026
Renewal Info
The report notes Texas must demonstrate compliance with federal Medicaid pharmacy requirements on a biannual basis, implying a recurring engagement for SUPPORT Act criteria review and reporting that may renew every two years.
More from ACENTRA HEALTH
More from Texas Health and Human Services
Texas Health and Human Services Interagency Contracts with Institutions of Higher Education Report 2026-05-21
Texas Health and Human Services Interagency Contracts with Institutions of Higher Education Report 2026-05-21
Texas Health and Human Services Interagency Contracts with Institutions of Higher Education Report 2026-05-21
Texas Health and Human Services Interagency Contracts with Institutions of Higher Education Report 2026-05-21
Texas Health and Human Services Interagency Contracts with Institutions of Higher Education Report 2026-05-21
Get alerts on contract renewals, new awards, and vendor activity.
See live SLED buying signals, source docs, decision-makers, contract context, and the next step into your CRM or pipeline.